Lightpoint Medical - features in news

The case for building Lightpoint Technologies' Cherenkov Luminescence Imaging (CLI) system into breast cancer surgery is building. This article indicates how trials show that there is a tangible prospect of completely clearing the cancer with a single operation, thereby reducing the number of breast cancer patients requiring a repeat surgical procedure, a costly and stressful feature of today's breast cancer treatment.

In the Life Sciences sector, an important theme followed by Ruffena Capital in engaging with clients is the realistic prospect of reducing direct costs whilst at the same time delivering improvements in healthcare.

This is a great example of a client putting this theme into practice.

The Innovation of the Year Award confirms the opinion of others on this point.

Simon Heywood, Director, Life Sciences, Ruffena Capital